Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.

Details

Serval ID
serval:BIB_65744C0AFDC2
Type
Article: article from journal or magazin.
Publication sub-type
Letter (letter): Communication to the publisher.
Collection
Publications
Institution
Title
Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.
Journal
The British journal of dermatology
Author(s)
Brunner P.M., Conrad C., Vender R., Grond S., Schuster C., Patel H., Xu W., Carrascosa Carrillo J.M.
ISSN
1365-2133 (Electronic)
ISSN-L
0007-0963
Publication state
Published
Issued date
10/2021
Peer-reviewed
Oui
Volume
185
Number
4
Pages
865-867
Language
english
Notes
Publication types: Letter ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Eczema and eczematous reactions induced by interleukin (IL)-17 inhibitors in patients with psoriasis are established adverse events (1), which may be reported as adverse events (AEs) in up to 12.1% patients on anti-IL-17 treatment in controlled clinical trials (2-5). We performed an integrated safety analysis of 13 clinical studies to evaluate the frequency and management of the treatment-emergent adverse events (TE-AEs) of eczema and clinical variants in patients with moderate-to-severe psoriasis treated with ixekizumab (IXE), a selective inhibitor of IL-17A, to better understand the nature of these events.
Keywords
Antibodies, Monoclonal, Humanized/adverse effects, Dermatologic Agents/adverse effects, Etanercept/adverse effects, Humans, Psoriasis/drug therapy, Severity of Illness Index, Treatment Outcome, Ustekinumab/adverse effects
Pubmed
Web of science
Open Access
Yes
Create date
14/06/2021 9:32
Last modification date
28/05/2022 6:34
Usage data